Cancer Clinical Trial
— COACH-CogOfficial title:
Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision
Building upon prior work, the investigator team developed a communication intervention for older adults with ADRD who are considering a decision about cancer management (adapted intervention: COACH-Cog). The investigators hypothesize that for patients with dual diagnoses of ADRD and cancer, COACH-Cog will increase autonomy support of care partners and patients in the decision-making process, leading to greater acknowledgement and support of cognitive concerns and cognitive-related goals, thereby improving goal concordant care. The investigators are conducting a pilot randomized controlled trial (RCT; cluster randomized by physician) including approximately 45 oncology clinicians and 130 patient/care partner dyads evaluating the effect of COACH-Cog on care partner and patient autonomy support, care partner well-being, goal-concordance, and communication.
Status | Recruiting |
Enrollment | 305 |
Est. completion date | October 2027 |
Est. primary completion date | April 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | PATIENTS: Patient Inclusion Criteria: 1. Be age 65 or older 2. Have a clinical diagnosis of Alzheimer's disease or related dementia (ADRD [Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, or dementia of unknown subtype]) 3. Have a clinical diagnosis of cancer (any type or stage) 4. Anticipate a potential decision about cancer-related management, as confirmed by the patient's primary medical oncology clinician. 5. Have a care partner willing and able to participate in the study 6. Are able to read and understand English. The communication coaching session will be delivered in English, thus necessitating this requirement. 7. Be able to provide informed consent (as measured by UBACC) or have a Legally Authorized Representative to provide informed consent Patient Exclusion Criteria: Patient exclusion criteria: None CARE PARTNER: Care partner inclusion criteria: 1. Age 18 or over 2. Able to read and understand spoken English 3. Able to provide informed consent Care partner exclusion criteria: None ONCOLOGY CLINICIAN: Oncology clinician inclusion criteria: 1. Oncology clinicians affiliated with the Wilmot Cancer Institute 2. Do not intend to move or retire within the next 2 years. Oncology clinician exclusion criteria: None |
Country | Name | City | State |
---|---|---|---|
United States | University of Rochester Wilmot Cancer Institute | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
University of Rochester | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient: Patient-Centered Communication in Cancer Care (PCC-Ca) | Patient communication; score range 1-5; higher scores are better | 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter | |
Other | Patient: Health Care Climate Questionnaire (HCCQ) | Patient autonomy support; score range: 6-42; higher score is better. | 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter | |
Other | Patient: Health Care Climate Questionnaire - Age (HCCQ-Age) | Patient Age-related autonomy support; score range 0-28; higher scores are worse | 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter | |
Other | Patient Decision Regret Scale | Patient: Decision regret; score range 5-25; higher score is worse | 3-months post-oncology clinical encounter | |
Other | Physician Decision Regret Scale | Physician: Decision regret; score range 5-25; higher score is worse | 3-months post-oncology clinical encounter | |
Primary | Care Partner: Health Care Climate Questionnaire (HCCQ) | Care Partner autonomy support; score range: 6-42; higher score is better. | 4-weeks post oncology clinical encounter | |
Secondary | Montgomery Borgatta Caregiving Burden Scale | Care partner well-being: Caregiver burden; total score range 14-70; range for subscales 4-30; higher score is better for Objective Subscale; Higher score is worse for Subjective Stress and Subjective Demand subscales | 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter | |
Secondary | World Health Organization Quality of Life Brief Version (WHOQOL-BREF) | Care partner well-being: Quality of Life; Total score range 26-130; domain range 3-40; higher score is better | 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter | |
Secondary | Care Partner PROMIS Depression | Care partner well-being: Depression; score range 4-20; higher score is worse | 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter | |
Secondary | Care partner PROMIS Anxiety | Care partner well-being: Anxiety; score range 4-20; higher score is worse | 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter | |
Secondary | Care partner: Patient-Centered Communication in Cancer Care (PCC-Ca) | Care partner communication; score range 1-5; higher scores are better | 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter | |
Secondary | Care partner: Health Care Climate Questionnaire - Age (HCCQ-Age) | Care partner Age-related autonomy support; score range 0-28; higher scores are worse | 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter | |
Secondary | Care partner: Qualitative assessment of goal concordance | Care partner: Goal concordance; qualitative analysis if goal concordance occurred (yes/no); range 0-130; higher number better | 3-months post-oncology clinical encounter | |
Secondary | Care partner: Decision Regret Scale | Care partner: Decision regret; score range 5-25; higher score is worse | 3-months post-oncology clinical encounter |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|